Literature DB >> 33153897

Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer.

Arpeet T Shah1, Roberto J Bernardo2, Gerald J Berry3, Kristina Kudelko2, Heather A Wakelee4.   

Abstract

Entities:  

Keywords:  Adenocarcinoma; Lorlatinib; NSCLC; PTTM; Pulmonary hypertension

Mesh：

Substances：

Year:  2020        PMID： 33153897     DOI： 10.1016/j.cllc.2020.09.020

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  2 in total

Review 1.  ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.

Authors:  Sébastien Gendarme; Olivier Bylicki; Christos Chouaid; Florian Guisier
Journal:  Curr Oncol       Date:  2022-01-28       Impact factor: 3.677

2.  Crizotinib for ROS1-rearranged lung cancer and pulmonary tumor thrombotic microangiopathy under venoarterial extracorporeal membrane oxygenation.

Authors:  Daisetsu Aoyama; Shigefumi Fukui; Haruhiko Hirata; Keiko Ohta-Ogo; Hideo Matama; Emi Tateishi; Tatsuya Nishii; Yasuhide Asaumi; Mamoru Toyofuku; Tatsuyoshi Ikeue; Takeshi Ogo; Hatsue Ishibashi-Ueda; Satoshi Yasuda
Journal:  Pulm Circ       Date:  2022-02-21       Impact factor: 2.886
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.